^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    irinotecan

    i
    Other names: CPT-11, CPT 11, DQ 2805, IHL-305, SN 38B11, U 101440E
    Company:
    Generic mfg.
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    1d
    Role of somatic mutations in Homologous Recombination (HR) and DNA Damage Repair (DDR) genes in metastatic pancreatic ductal adenocarcinoma (mPDAC) (AIOM 2024)
    Background : First-line therapy’s (tx) choice between the two most efficacious approved regimens (FOLFIRINOX and Gemcitabine plus Nab-Paclitaxel - GemNab) in mPDAC is usually based on patients’ (pts) baseline characteristics... HR-DDR somatic alterations emerged as possible predictor of lower benefit from platinum-free regimens. Thus, platinum-based regimens should be preferred in this setting. Validation in wider cohorts and correlation with HR-DDR germline mutations are warranted.
    PARP Biomarker • Metastases
    |
    TruSight Oncology 500 Assay
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium
    1d
    The presence of liver metastases does not predict resistance to immunotherapy in proficient MMR metastatic colorectal cancer (mCRC): a secondary analysis of the AtezoTRIBE study (AIOM 2024)
    We performed a comprehensive evaluation of liver-metastatic (LM) disease among mCRC patients enrolled in the phase II randomized AtezoTRIBE trial, that showed a modest benefit from the addition of atezolizumab (atezo) to 1st line FOLFOXIRI/bevacizumab (bev) and identified Immunoscore IC as a predictor of ICI efficacy in the proficient mismatch repair (pMMR) population... In our cohort of pMMR mCRC patients, the immune microenvironment of tumors with LM spread does not differ from that of tumors with no liver involvement. The presence or not of LM disease does not affect the efficacy of adding atezo to first-line FOLFOXIRI/bev, differently than Immunoscore IC.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    DetermaIO™ • Immunoscore® IC Assay
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1d
    Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): results from the comprehensive genomic profiling (CGP) trial FPG500 (AIOM 2024)
    Background : Treatment (tx) of MSS/MMRp mCRC relies mainly on oxaliplatin (oxa)- or irinotecan-based doublet chemotherapy regimens, with no biomarker reported so far, allowing the selection of one tx over the other. HR-DDRa is associated with MSI-H or TMB-H. Pts with MSS HR-DDRa tumors benefit from oxa-based first line treatment. Longer FU, allowing mature OS data, and wider cohorts are warranted.
    Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • BAP1 (BRCA1 Associated Protein 1) • PALB2 (Partner and localizer of BRCA2) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCL (FA Complementation Group L) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
    |
    TMB-H • MSI-H/dMMR
    |
    TruSight Oncology 500 Assay
    |
    oxaliplatin • irinotecan
    1d
    RAS/BRAF testing of circulating tumor DNA (ctDNA) in tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the LIquid BIopsy monoclonal Antibodies (LIBImAb) Study (AIOM 2024)
    The LIBImAb Study is a phase III, randomized, openlabel, comparative, multi-center trial to assess the superiority in terms of efficacy of bevacizumab versus cetuximab in combination with FOLFIRI in mCRC pts, RAS/BRAFwt on tumor tissue and RAS/BRAF mutant (RAS/BRAFmut) at liquid biopsy... These data indicate the feasibility of cfDNA-based prospective enrolment in an interventional trial using a test with a rapid TAT for screening of RAS/ BRAF status in plasma. Our preliminary findings also suggest that ctDNA testing might better recapitulate the tumor heterogeneity of mCRC pts thus complementing tissue genomic profiling.
    Clinical • Liquid biopsy • Circulating tumor DNA • Metastases • Biopsy
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RAS (Rat Sarcoma Virus)
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF wild-type • RAS mutation • RAS wild-type • RAS wild-type + BRAF wild-type
    |
    Idylla™ ctKRAS Mutation Test
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium
    1d
    Clinicopathologic feature and treatment progress of high-grade ovarian neuroendocrine tumors. (PubMed, Med Oncol)
    Primary treatment strategies predominantly involve surgical intervention coupled with etoposide-cisplatin combination chemotherapy. In cases of recurrence, second-line chemotherapeutic agents including paclitaxel, irinotecan, and doxorubicin are commonly employed alongside localized radiotherapy. While specific genetic mutations remain elusive, emerging evidence suggests potential therapeutic effect involving mTOR inhibitors, PD-1 monoclonal antibodies, and antiangiogenic agents based on isolated case reports. The exploration of representative set of mutations will help for precise targeted therapies and remains a focal point of our ongoing research efforts.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
    |
    cisplatin • paclitaxel • doxorubicin hydrochloride • etoposide IV • irinotecan
    2d
    Clinicopathologic features and treatment efficacy of patients with BRAF V600E-mutated metastatic colorectal cancer: a multi-center real-world propensity score matching study. (PubMed, BMC Cancer)
    The overall prognosis of BRAF V600E mutant mCRC patients is poor. Poor differentiation and liver metastases were negative independent prognostic factors for OS. First-line triplet-drug therapy was associated with better OS, especially in patients with good physical condition and high tumor burden.
    Journal • Real-world evidence • Real-world • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    2d
    DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol. (PubMed, BMC Cancer)
    This study will determine the prevalence of DPYD gene variant status in Australia and its impact on FP-induced toxicity among Australians with cancer. Feasibility and cost-effectiveness for Australian health care system will be estimated to support national roll-out of prospective DPYD genotyping prior to FP administration. Additionally, feasibility will be confirmed with the intention of including UGT1A1 in future pharmacogenomic panels to aid chemotherapy prescribing.
    Clinical protocol • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    UGT1A1*1*1
    |
    5-fluorouracil • irinotecan
    2d
    KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration. (PubMed, JCO Precis Oncol)
    A detail estimation of KRASG12D mut mCRC patients' characteristics and expected outcomes may be useful when planning future studies in this subgroup. The high prevalence of PI3K/PTEN/Akt pathway activating alterations may affect the efficacy of targeted strategies.
    Journal • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • KRAS mutation • NRAS mutation • PIK3CA mutation • BRAF V600 • KRAS G12D • RAS mutation • KRAS G12
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    3d
    Identification of basement membrane-related prognostic model associated with the immune microenvironment and synthetic therapy response in pancreatic cancer: integrated bioinformatics analysis and clinical validation. (PubMed, J Cancer)
    PCs with a low BM-related score had a better outcome and were more likely to benefit from oxaliplatin, irinotecan, and KRAS(G12C) inhibitor-12, and immunotherapy. Molecular docking indicated that epigallocatechin gallate had a strong binding activity with DSG3, MET, and PLAU and may be used as a potential therapeutic agent for PC. In conclusion, this study developed a BM-related model associated with PC prognosis, immune infiltration, and treatment, which provided new insights into PC stratification and drug intervention.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • PLAU (Plasminogen Activator)
    |
    oxaliplatin • irinotecan
    3d
    Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials. (PubMed, Cancers (Basel))
    The efficacy results showed a significantly greater clinical benefit with sacituzumab govitecan compared to standard chemotherapy in patients with triple-negative breast cancer. This drug will become a treatment of substantial impact in future treatment guidelines for this type of cancer.
    Clinical • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    irinotecan • Trodelvy (sacituzumab govitecan-hziy)
    3d
    TORPEDO: Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=160, Recruiting, Cancer Research Antwerp
    New trial • Metastases
    |
    albumin-bound paclitaxel • irinotecan
    3d
    Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer. (PubMed, Future Oncol)
    We aim to assess the addition of XB2001 (anti-IL-1 alpha monoclonal antibody) plus trifluridine/tipiracil-bevacizumab in mCRC refractory to standard chemotherapy. This multicenter, randomized, double blind, non-comparative Phase I-II study (ClinicalTrials.gov NCT05201352) will assess the efficacy and safety of trifluridine/tipiracil-bevacizumab and XB2001 in patients with mCRC previously treated for metastatic disease by chemotherapy treatment including oxaliplatin, irinotecan, 5-FU, antiangiogenic and/or anti-EGFR if indicated...Primary end point of Phase II is the efficacy of trifluridine/tipiracil-bevacizumab + XB2001 in term of 6-month overall survival. Ancillary analysis will be performed.
    P1/2 data • Journal • Metastases
    |
    IL1A (Interleukin 1, alpha)
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil)
    4d
    An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • magrolimab (ONO-7913) • levoleucovorin calcium
    6d
    Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Memorial Sloan Kettering Cancer Center
    Trial completion date • Trial primary completion date
    |
    temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • mesna • dexrazoxane
    6d
    A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (clinicaltrials.gov)
    P1, N=750, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium
    6d
    TRIPP-FFX: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=80, Recruiting, OncoSil Medical Limited | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    UGT1A1*1*1
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    6d
    The Sagittarius Trial (clinicaltrials.gov)
    P3, N=700, Recruiting, IFOM ETS - The AIRC Institute of Molecular Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Signatera™
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • 5-fluorouracil • Vectibix (panitumumab) • Perjeta (pertuzumab) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    6d
    Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Recruiting, Yale University | Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    oxaliplatin • irinotecan
    8d
    Study on Cadonilimab Plus mFOLFIRINOX in patients with locally advanced pancreatic cancer (ChiCTR2400088986)
    P=N/A, N=30, Not yet recruiting, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New trial • Metastases
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    oxaliplatin • irinotecan • Kaitanni (cadonilimab)
    8d
    Synergistic effect of ultrasound therapy in chemotherapy for unresectable pancreatic cancer (ChiCTR2400090269)
    P3, N=151, Not yet recruiting, The Third Affiliated Hospital of Sun Yat-sen University; The Third Affiliated Hospital of Sun Yat-sen University
    New P3 trial
    |
    irinotecan
    10d
    NEO-IMPACT: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer (ACTRN12622000378729)
    P2, N=20, Active, not recruiting, Australasian Gastro-Intestinal Trials Group (AGITG) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    5-fluorouracil • oxaliplatin • irinotecan
    10d
    RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2/3, N=429, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial primary completion date • Metastases
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    10d
    Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02) (clinicaltrials.gov)
    P2, N=114, Not yet recruiting, Institut Cancerologie de l'Ouest
    New P2 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan
    10d
    Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2, N=126, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P2 trial • Metastases
    |
    paclitaxel • Cyramza (ramucirumab) • irinotecan • Lonsurf (trifluridine/tipiracil) • bemarituzumab (AMG 552)
    11d
    Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Pardis Noor Medical Imaging and Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Initiation date: Apr 2024 --> Apr 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Avastin (bevacizumab) • irinotecan
    11d
    CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=520, Completed, Taizhou Mabtech Pharmaceutical Co.,Ltd | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF wild-type
    |
    irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)
    11d
    CIFRA: Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (clinicaltrials.gov)
    P2, N=34, Recruiting, National Cancer Institute, Naples | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD163 (CD163 Molecule) • GZMB (Granzyme B) • TGFB1 (Transforming Growth Factor Beta 1) • FOXP3 (Forkhead Box P3) • CD86 (CD86 Molecule)
    |
    KRAS wild-type • BRAF wild-type • NRAS wild-type • CD163 expression
    |
    Erbitux (cetuximab) • 5-fluorouracil • irinotecan
    12d
    NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (clinicaltrials.gov)
    P2, N=62, Recruiting, New Approaches to Neuroblastoma Therapy Consortium | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    temozolomide • irinotecan • Unituxin (dinutuximab) • Leukine (sargramostim)
    13d
    TTX-080-001: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=240, Recruiting, Tizona Therapeutics, Inc | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Jun 2027
    Enrollment open • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
    13d
    Efficacy and safety of Shengjiang Xiexin decoction on irinotecan-induced diarrhea in small cell lung cancer patients: a multicenter, randomized, double-blind, placebo-controlled trial. (PubMed, Chin Med)
    SXD had a prophylactic effect in the diarrhea induced by irinotecan, especially for UGT1A1 high-risk population, and this effect from SXD appeared to be maintained the completion of chemotherapy schedule. The mechanism of action of SXD was related to the regulation of inflammatory factors. Trial registration Chinese Clinical Trial Register: ChiCTR1800018490. Registered on 20 September 2018. https://www.chictr.org.cn/showproj.html?proj=25250 . The preliminary protocol of this clinical study has been published in the journal "Trials" in the form of protocol before this paper (Deng et al. in Trials 21:370, 2020).
    Clinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • IL10 (Interleukin 10) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta)
    |
    UGT1A1*1*1
    |
    irinotecan
    13d
    Computational identification of PDL1 inhibitors and their cytotoxic effects with silver and gold nanoparticles. (PubMed, Sci Rep)
    Their conjugation with the drugs Irinotecan, Imatinib, and Methotrexate was also confirmed using UV-Vis, FTIR, and Dynamic light scattering (DLS). The result of the methylthiazol tetrazolium (MTT) assay showed that conjugated AgNPs and AuNPs with Irinotecan had a higher toxic effect on the A549 cancer cell line than AgNPs and AuNPs conjugated with Imatinib. This study provides a promising avenue for further investigation and development of nanoparticle-drug conjugates as a potential cancer immunotherapy strategy.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    imatinib • irinotecan • methotrexate
    14d
    Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=65, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • Neupogen (filgrastim) • dexrazoxane
    14d
    A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, Inspirna, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2028 --> Dec 2026 | Trial primary completion date: Aug 2026 --> Sep 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • ompenaclid (RGX-202)
    14d
    The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. (PubMed, Biomed Pharmacother)
    p21CIP1 is essentially involved in induction and maintenance of irinotecan-induced senescence. Neither p16INK4A, p14ARF, nor PTEN contribute to senescence, if p21CIP1 cannot be induced. Based on the positive results of the irinotecan/BV6 treatment, combatting recurrent glioblastomas by targeting senescence cell antiapoptotic pathways (SCAPs) should be considered.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    temozolomide • irinotecan
    15d
    Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort. (PubMed, Eur J Cancer)
    Results suggest that aflibercept plus FOLFIRI, after failure of a prior oxaliplatin-based regimen, allows R0/R1 resection of CLM in almost 20 % of patients with a major pathological response in most cases and a median OS prolonged by more than 3-fold versus non-resected patients.
    Journal
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF mutation • RAS mutation
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    17d
    Rapid Administration Pilot for Infusing Dinutuximab (clinicaltrials.gov)
    P4, N=11, Suspended, Children's Hospital Los Angeles | Trial completion date: Aug 2024 --> Jun 2025 | Recruiting --> Suspended | Trial primary completion date: Aug 2024 --> Jun 2025
    Trial completion date • Trial suspension • Trial primary completion date
    |
    temozolomide • cyclophosphamide • irinotecan • topotecan • Unituxin (dinutuximab)
    17d
    Biomarcer-2 :Biomarker informed optimal management of advanced RAS wild type colorectal cancer (ACTRN12623000874617)
    P2, N=29, Recruiting, Australasian Gastrointestinal Trials Group | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus) • AREG (Amphiregulin) • EREG (Epiregulin)
    |
    BRAF wild-type • AREG expression
    |
    Erbitux (cetuximab) • irinotecan
    17d
    TTX-080-001: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
    17d
    FollowTheDIN: Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas (clinicaltrials.gov)
    P3, N=40, Recruiting, N.N. Petrov National Medical Research Center of Oncology
    New P3 trial
    |
    carboplatin • docetaxel • temozolomide • doxorubicin hydrochloride • irinotecan • Qarziba (dinutuximab beta)
    18d
    Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice. (PubMed, J Clin Oncol)
    Reporting PGx variants from germline WGS relevant to patients with cancer alongside primary findings related to their cancer can be clinically informative, informing prescribing to reduce the risk of ADRs. Extending the range of actionable variants to those found in patients of non-European ancestry is important and will extend the potential clinical impact.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase) • NUDT15 (Nudix Hydrolase 15)
    |
    UGT1A1*1*1
    |
    5-fluorouracil • capecitabine • irinotecan • mercaptopurine • thioguanine
    18d
    Prognostic Significance of Inflammation-based Scores in Pancreatic Cancer Patients Treated With Palliative Chemotherapy: A Single Institution Experience. (PubMed, In Vivo)
    The current analysis showed an association between inflammatory-based prognostic markers and overall survival in patients with metastatic pancreatic cancer treated in a real-world setting at a single institution.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    gemcitabine • albumin-bound paclitaxel • irinotecan
    18d
    Immunoliposomes for Neuroblastoma: Review of the Past Experience and Design of a Novel Nanoparticle. (PubMed, Anticancer Res)
    PEGylated anti-GD2-IL may allow NBL tropism. A size of approximately 100 nm could allow vascular permeability and packaging of oxamate in amounts needed for profound/selective lactate dehydrogenase-A inhibition. Thus, oxamate-loaded GD2-ILs may allow exploring the great translational potential of Warburg effect inhibition in GD2-positive cancers.
    Review • Journal
    |
    LDHA (Lactate dehydrogenase A) • BIRC5 (Baculoviral IAP repeat containing 5) • IL15 (Interleukin 15)
    |
    doxorubicin hydrochloride • etoposide IV • irinotecan